Press releases

XNK Therapeutics today announced that its CEO Johan Liwing will present at ABG Sundal Collier’s Life Science Summit in Stockholm, Sweden, on May 31 at 10:00am CEST.

XNK Therapeutics AB (“XNK”) today announced that the company’s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company.

XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This certificate allows the company to take control of the complete manufacturing chain, from withdrawal of blood from the patient at the clinic to the delivery of the finished autologous NK-cell based medicinal product.

XNK Therapeutics AB today announced its extensive participation at the 8[th] Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.

XNK Therapeutics today announced that it has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies.

XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Therapy event on February 22 between 09:00-12:00 CET.

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer (CMO), effective immediately. Dr. Hovstadius will be a member of the company’s management team. Dr. Johan Aschan who retires from his position as CMO will continue as the company’s Senior Medical Advisor.

XNK Therapeutics AB (“XNK”) today announced that the first patient has donated cells in the recently initiated preclinical evaluation of the autologous NK cell product XNK03 in locally advanced or metastatic urothelial cancer. The study is performed in collaboration with Anders Ullén’s research group at the Karolinska University Hospital, Stockholm, Sweden.

XNK Therapeutics AB (“XNK”) today said the company would continue its partnership with the Karolinska Cell Therapy Center’s production unit Vecura under the lead of Pontus Blomberg and Veronique Chotteau’s group in Cell Technology from the Swedish Royal Institute of Technology as part of a collaboration within The Competence Centre for Advanced BioProduction by Continuous Processing, AdBIOPRO.

XNK Therapeutics AB (“XNK”) today announced it will adopt the generic name evencaleucel for its lead candidate targeting multiple myeloma. Evencaleucel was recently recommended by the World Health Organization (WHO) as the International Nonproprietary Name (INN) for XNK’s leading drug candidate.

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Anna-Karin Maltais as Chief Scientific Officer, effective October 17[th]. She will be a member of the company’s management team.

XNK Therapeutics AB (“XNK”) today announced the successful completion of the building phase of the company’s new GMP clean room facility.

XNK Therapeutics AB (“XNK”) today announced it is initiating a program targeting urothelial cancer, the most common form of bladder cancer. This is the first project where XNK’s proprietary technology platform of natural killer (NK) cell therapies is applied towards solid tumors. The company will collaborate with the Karolinska University Hospital in Solna, Sweden.

XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate drug was presented at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9[th]-12[th].

XNK Therapeutics AB (“XNK”) today announced that Ted Fjällman, Partner at Flerie Invest, has joined the company’s board of directors.

XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its leading candidate drug has been selected for a presentation at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9[th]-12[th].

XNK Therapeutics AB (“XNK”) today announced it has secured a private placement of SEK 132 million, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development in multiple myeloma and other indications.

XNK Therapeutics AB (“XNK”) today announced that the first patient has been treated in a Phase II clinical study using XNK’s leading autologous natural killer (NK) cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab).

XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Therapy event on February 23 at 09.50 CET. The presentation is broadcasted live and can be followed at: https://www.redeye.se/events/825130/redeye-theme-regenerative-medicine-cell-therapy

XNK Therapeutics AB (“XNK”) today announced that the first-in-human Phase I study ACP-001, performed at the Karolinska University Hospital in Huddinge, Sweden, has been published in Cell Reports Medicine. The study demonstrates that XNK’s autologous natural killer (NK) cell-based immunotherapy is feasible. Furthermore, it shows a good safety profile and promising efficacy data as consolidation treatment following autologous stem cell transplantation in patients newly diagnosed with multiple myeloma.

XNK Therapeutics AB’s CEO, Johan Liwing, will present at the ABGSC Private Companies event on December 6. The presentation starts at 09:30CET and will be livestreamed via https://www.introduce.se.

XNK Therapeutics AB (“XNK”) today announced the strengthening of the company’s expertise by the appointment of Ola Landgren, M.D., Ph.D., Fredrik Schjesvold M.D., Ph.D. and Johan Lund M.D., Ph.D. These scientific advisors are key to the company’s plan to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies within plasma cell disorders and hematological malignancies.

September 29, 2021

XNK Therapeutics AB (“XNK”) today announced plans to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline. The company will begin the preclinical and commercial work to expand the pipeline and expects to announce a decision in Q1 2022.